Inhibition of collagen i accumulation reduces glomerulosclerosis by a Hic-5-dependent mechanism in experimental diabetic nephropathy

Laboratory Investigation

Volumn 93, Issue 5, 2013, Pages 553-565

  Hornigold, Nick ^a   Johnson, Tim S ^b   Huang, Linghong ^b   Haylor, John L ^b   Griffin, Martin ^c   Mooney, Andrew ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

collagen I; glomerulosclerosis; Hic 5; mesangial cell

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CREATININE; ENZYME INHIBITOR; NTU 281; PROTEIN; PROTEIN HIC 5; TRANSGLUTAMINASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; GLOMERULOSCLEROSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MESANGIUM CELL; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT;

ACTINS; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; COLLAGEN TYPE I; CREATININE; CYTOSKELETAL PROTEINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DNA-BINDING PROTEINS; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; LIM DOMAIN PROTEINS; MALE; MESANGIAL CELLS; NEPHRECTOMY; PROTEINURIA; RATS; RATS, WISTAR;

EID: 84877267575     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.42     Document Type: Article

References (43)

1. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005;98:S7-S10.
2. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213-217.
3. Johnson RJ, Floege J, Yoshimura A, et al. The activated mesangial cell: a glomerular "myofibroblast"? J Am Soc Nephrol 1992;2(10 Suppl): S190-S197.
4. Young BA, Johnson RJ, Alpers CE, et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995;47:935-944.
5. Couchman JR, Beavan LA, McCarthy KJ. Glomerular matrix: synthesis, turnover and role in mesangial expansion. Kidney Int 1994;45: 328-335.
6. Hornigold N, Craven RA, Keen JN, et al. Upregulation of Hic-5 in glomerulosclerosis and its regulation of mesangial cell apoptosis. Kidney Int 2010;77:329-338.
7. Nishiya N, Tachibana K, Shibanuma M, et al. Hic-5-reduced cell spreading on fibronectin: competitive effects between paxillin and Hic-5 through interaction with focal adhesion kinase. Mol Cell Biol 2001;21:5332-5345.
8. Shibanuma M, Kim-Kaneyama JR, Ishino K, et al. Hic-5 communicates between focal adhesions and the nucleus through oxidant-sensitive nuclear export signal. Mol Biol Cell 2003;14:1158-1171.
9. Kim-Kaneyama J, Shibanuma M, Nose K. Transcriptional activation of the c-fos gene by a LIM protein, Hic-5. Biochem Biophys Res Commun 2002;299:360-365.
10. Panetti TS, Hannah DF, Avraamides C, et al. Extracellular matrix molecules regulate endothelial cell migration stimulated by lysophosphatidic acid. J Thromb Haemost 2004;2:1645-1656.
11. Yuminamochi T, Yatomi Y, Osada M, et al. Expression of the LIM proteins paxillin and Hic-5 in human tissues. J Histochem Cytochem 2003;51:513-521.
12. Shibanuma M, Iwabuchi Y, Nose K. Possible involvement of hic-5, a focal adhesion protein, in the differentiation of C2C12 myoblasts. Cell Struct Funct 2002;27:21-27.
13. Ishino K, Kaneyama, Shibanuma M, et al. Specific decrease in the level of Hic-5, a focal adhesion protein, during immortalization of mouse embryonic fibroblasts, and its association with focal adhesion kinase. Journal Cell Biochem 2000;76:411-419.
14. Kim-Kaneyama JR, Wachi N, Sata M, et al. Hic-5, an adaptor protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Biochem Biophys Res Commun 2008;376:682-687.
15. Hu Y, Cascone PJ, Cheng L, et al. Lepidopteran DALP, and its mammalian ortholog HIC-5, function as negative regulators of muscle differentiation. Proc Natl Acad SciUSA 1999;96:10218-10223.
16. Skill NJ, Johnson TS, Coutts IG, et al. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J Biol Chem 2004;279:47754-47762.
17. Kleman JP, Aeschlimann D, Paulsson M, et al. Transglutaminasecatalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells. Biochemistry 1995;34:13768-13775.
18. Fisher M, Jones RA, Huang L, et al. Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. Matrix Biol 2009; 28:20-31.
19. Huang L, Haylor JL, Hau Z, et al. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int 2009; 76:383-394.
20. Johnson TS, Fisher M, Haylor JL, et al. Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol 2007;18:3078-3088.
21. Kitamura M, Kawachi H. Creation of an in vivo cytosensor using engineered mesangial cells. Automatic sensing of glomerular inflammation controls transgene activity. J Clin Invest 1997;100:1394-1399.
22. Mooney A, Jackson K, Bacon R, et al. Type IV collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis via beta(1) integrin-mediated survival signals. Am J Pathol 1999;155: 599-606.
23. Mooney A, Jobson T, Bacon R, et al. Cytokines promote glomerular mesangial cell survival in vitro by stimulus-dependent inhibition of apoptosis. J Immunol 1997;159:3949-3960.
24. Yokoo T, Kitamura M. IL-1beta depresses expression of the 70-kilodalton heat shock protein and sensitizes glomerular cells to oxidant-initiated apoptosis. J Immunol 1997;159:2886-2892.
25. Lovett DH, Sterzel RB. Cell culture approaches to the analysis of glomerular inflammation. Kidney Int 1986;30:246-254.
26. Baker AJ, Mooney A, Hughes J, et al. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 1994; 94:2105-2116.
27. Hornigold N, Craven RA, Keen JN, et al. Upregulation of Hic-5 in glomerulosclerosis and its regulation of mesangial cell apoptosis. Kidney Int 2010;77:329-338.
28. Hartner A, Veelken R, Wittmann M, et al. Effects of diabetes and hypertension on macrophage infiltration and matrix expansion in the rat kidney. BMC Nephrol 2005;6:6.
29. Kim-Kaneyama JR, Takeda N, Sasai A, et al. Hic-5 deficiency enhances mechanosensitive apoptosis and modulates vascular remodeling. J Mol Cell Cardiol 2011;50:77-86.
30. Zhang J, Zhang LX, Meltzer PS, et al. Molecular cloning of human Hic-5, a potential regulator involved in signal transduction and cellular senescence. Mol Carcinog 2000;27:177-183.
31. Hu Y, Cascone PJ, Cheng L, et al. Lepidopteran DALP, and its mammalian ortholog HIC-5, function as negative regulators of muscle differentiation. Proc Natl Acad Sci USA 1999;96:10218-10223.
32. Suga K, Kondo S, Matsuura S, et al. Glomerular expression of hydrogen peroxide-inducible clone-5 in human and rat progressive mesangial proliferative glomerulonephritis. Nephron Exp Nephrol 2012;120: e59-e68.
33. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
34. Kaname S, Uchida S, Ogata E, et al. Autocrine secretion of transforming growth factor-beta in cultured rat mesangial cells. Kidney Int 1992;42:1319-1327.
35. Shibanuma M, Mashimo J, Kuroki T, et al. Characterization of the TGF beta 1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem 1994;269:26767-26774.
36. Kojima S, Nara K, Rifkin DB. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 1993;121:439-448.
37. Nunes I, Gleizes PE, Metz CN, et al. Latent transforming growth factorbeta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 1997;136:1151-1163.
38. Huang L, Haylor JL, Fisher M, et al. Do changes in transglutaminase activity alter latent transforming growth factor beta activation in experimental diabetic nephropathy? Nephrol Dial Transplant 2010;25:3897-3910.
39. Zhang J, Zhang LX, Meltzer PS, et al. Molecular cloning of human Hic-5, a potential regulator involved in signal transduction and cellular senescence. Mol Carcinog 2000;27:177-183.
40. Oka C, Tsujimoto R, Kajikawa M, et al. HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development 2004;131:1041-1053.
41. Murwantoko YM, Ueta Y, Murasaki A, et al. Binding of proteins to the PDZ domain regulates proteolytic activity of HtrA1 serine protease. Biochem J 2004;381(Pt 3):895-904.
42. Xu Y, See WA. Regulation of plasminogen activator activity in transitional carcinoma cell lines by wound site growth factors. Surg Oncol 1994;3:175-185.
43. Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci 2009;14: 2028-2041.